Event dossier

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

1 report1 sourceSep 25, 2026, 12:51 PM
FilterCNBC
Clustered coverageCNBC
Coverage timeline1
Coverage timeline

Coverage timeline

Ranked reports inside the event cluster. Open any publisher link to read the original coverage.

CNBCSep 25, 2026, 12:51 PM

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Related events

Related events

Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.